The acquisition marks
In
Contact:
Investor
W1S 2HR
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761
Email: investors@hikma.uk.com
(C) 2022 Electronic News Publishing, source
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,828 GBX | -0.49% |
|
+0.96% | +2.14% |
Jun. 24 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
Jun. 20 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
The acquisition marks
In
Contact:
Investor
W1S 2HR
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761
Email: investors@hikma.uk.com
(C) 2022 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
+2.14% | 5.29B | |
+63.05% | 856B | |
+39.03% | 631B | |
-4.78% | 359B | |
+17.52% | 325B | |
+8.43% | 297B | |
+13.68% | 244B | |
+4.99% | 234B | |
+16.31% | 226B | |
+14.63% | 177B |